Leerink Partnrs Has Bearish Estimate for uniQure Q4 Earnings

uniQure N.V. (NASDAQ:QURE) – Equities research analysts at Leerink Partnrs decreased their Q4 2026 earnings estimates for uniQure in a research note issued on Monday, November 10th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings per share of $1.08 for the quarter, down from their previous estimate of $1.10. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share.

Several other equities research analysts have also recently weighed in on QURE. Wells Fargo & Company increased their target price on uniQure from $65.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Benchmark reiterated a “buy” rating on shares of uniQure in a research report on Tuesday, November 4th. Leerink Partners dropped their price objective on uniQure from $68.00 to $60.00 and set an “outperform” rating for the company in a research note on Monday. The Goldman Sachs Group lowered their price target on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. Finally, UBS Group set a $95.00 price target on shares of uniQure in a report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $66.08.

uniQure Trading Down 0.9%

NASDAQ QURE traded down $0.28 during trading on Wednesday, hitting $30.56. 322,840 shares of the company’s stock traded hands, compared to its average volume of 2,222,303. The stock has a fifty day moving average of $42.55 and a two-hundred day moving average of $24.50. uniQure has a 12-month low of $5.50 and a 12-month high of $71.50. The firm has a market cap of $1.68 billion, a P/E ratio of -7.68 and a beta of 0.59. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The business had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.46 million.

Insider Buying and Selling at uniQure

In related news, CEO Matthew C. Kapusta sold 226,316 shares of the business’s stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the sale, the chief executive officer owned 651,454 shares of the company’s stock, valued at $27,009,282.84. The trade was a 25.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Robert Gut sold 31,434 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $27.26, for a total transaction of $856,890.84. Following the transaction, the director directly owned 40,145 shares of the company’s stock, valued at $1,094,352.70. This represents a 43.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 314,560 shares of company stock valued at $12,362,568. Insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Vestal Point Capital LP boosted its holdings in uniQure by 58.4% in the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock worth $50,801,000 after acquiring an additional 1,767,572 shares in the last quarter. Aberdeen Group plc raised its position in shares of uniQure by 6.9% in the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after purchasing an additional 189,029 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in uniQure by 3.8% in the 1st quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company’s stock worth $29,213,000 after purchasing an additional 101,598 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in uniQure during the 2nd quarter valued at about $29,217,000. Finally, JPMorgan Chase & Co. increased its stake in uniQure by 471.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after purchasing an additional 1,491,486 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.